PARIS--(BUSINESS WIRE)--New clinical data presented today at EuroPCR 2011 demonstrate immediate and long-term health-related quality-of-life (HRQoL) benefits for patients receiving the Medtronic CoreValve® System from Medtronic, Inc. (NYSE: MDT). The favorable two-year results from the 18-French CoreValve multicenter prospective study are the largest set of CoreValve HRQoL data and the longest-term HRQoL data available from all transcatheter aortic valve implantation (TAVI) systems.
